Massive data analysis advances understanding of how immunotherapy works
What factors influence the success or failure of immunotherapy treatment in patients with advanced bladder cancer? Why do ...
The Lancet22h
Amyloid-related iatrogenic atrophy of the brain: data transparency is an urgent safety priority
More than 2 years since the original trial data for lecanemab in Alzheimer's disease was published,1 and over 1·5 years since approval by the US Food and Drug Administration, brain volume data have ...